Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recently completed clinical study titled ‘Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab’ aimed to demonstrate the efficacy of dupilumab in treating chronic spontaneous urticaria (CSU) in patients who remain symptomatic despite H1 antihistamine use. The study’s significance lies in its potential to offer a new treatment option for CSU patients who do not respond adequately to existing therapies.
The intervention tested in this study was dupilumab, a monoclonal antibody administered via subcutaneous injection. Dupilumab is intended to improve symptoms of CSU, including itch and hives, and enhance overall disease control and quality of life.
The study was designed as a randomized, double-blind, placebo-controlled, multi-center trial with a parallel-group intervention model. It employed quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors were blinded to the treatment allocation. The primary purpose was treatment efficacy.
The study began on December 11, 2019, with its primary completion on July 30, 2025, and the last update submitted on August 18, 2025. These dates are crucial as they mark the timeline of the study’s execution and the availability of its results.
The successful completion of this study and positive results could significantly impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as dupilumab may become a key player in the CSU treatment market. This development could enhance investor sentiment, especially given the competitive landscape in the pharmaceutical industry where effective treatments for CSU are in demand.
The study is now completed, with further details available on the ClinicalTrials portal.